<DOC>
	<DOCNO>NCT00860535</DOCNO>
	<brief_summary>This study evaluate gene expression signature ( Growth Factor Signature [ GFS ] ) biomarker response/resistance BRC-ABL oncogene inhibitor .</brief_summary>
	<brief_title>Growth Factor Signature ( GFS ) Pilot Study ( MK0000-098 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<criteria>Participant must histologically cytopathologically confirm blast phase Ph+ CML Ph+ ALL . Participant 18 year age day sign informed consent Participant must performance status 03 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale Participant least 30 percent blast peripheral blood ; least 30 percent lymphoblast peripheral blood bone marrow For Part II : Participant progress take imatinib unable tolerate imatinib , define discontinue imatinib treatment result nonhematologic toxic effect grade If female , participant either postmenopausal , free menses &gt; 2 year , surgically sterilize willing use 2 adequate barrier method contraception prevent pregnancy agree abstain heterosexual activity throughout study , start Visit 1 Female participant childbearing potential must negative serum urine pregnancy test ( beta hCG ) screen If male , participant surgically sterilize , agree use adequate method contraception , agree abstain heterosexual activity duration study Participant patrticipant 's legal representative voluntarily agree participate give write informed consent Participant must available periodic blood sampling , study related assessment , management treat institution duration study Participant currently participate participate study investigational compound device within 30 day 5 halflives , whichever longer , start treatment Participant know human immunodeficiency virus ( HIV ) infection HIVrelated malignancy Participant female pregnant breastfeeding , expect conceive within project duration study Participant know allergy hypersensitivity imatinib , dasatinib nilotinib Participant history current evidence condition , therapy , laboratory abnormality might confound result study , interfere participant 's participation full duration study , best interest participant participate Participant know psychiatric substance abuse disorder would interfere cooperation requirement trial There concern investigator regard safe participation participant study reason , investigator considers participant inappropriate participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>